INOZYME PHARMA, INC. Interest Expense Nonoperating
INOZYME PHARMA, INC. reported Interest Expense Nonoperating of $1.41 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2025-05-14
- INOZYME PHARMA, INC. interest expense nonoperating for the quarter ending 2025-03-31 was $1.41M, a 6.11% increase year-over-year.
- INOZYME PHARMA, INC. interest expense nonoperating for the quarter ending 2024-12-31 was $1.42M, a 11.01% increase year-over-year.
- INOZYME PHARMA, INC. interest expense nonoperating for the quarter ending 2024-09-30 was $1.42M, a 48.58% increase year-over-year.
- INOZYME PHARMA, INC. interest expense nonoperating for the quarter ending 2024-03-31 was $1.32M.
- INOZYME PHARMA, INC. interest expense nonoperating for fiscal 2024 was $5.56M, a 66.76% increase from fiscal 2023.
- INOZYME PHARMA, INC. interest expense nonoperating for fiscal 2023 was $3.33M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-03-31 | $1.41M 10-Q · filed 2025-05-14 | $2.83M derived: sum of 2 quarters · filed 2025-05-14 | $4.24M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2024-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $2.84M derived: sum of 2 quarters · filed 2025-03-10 | $5.56M 10-K · filed 2025-03-10 | |
| 2024-09-30 | $1.42M 10-Q · filed 2024-11-05 | $4.14M 10-Q · filed 2024-11-05 | ||
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-14 | $2.61M derived: sum of 2 quarters · filed 2025-05-14 | $3.56M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $2.23M derived: sum of 2 quarters · filed 2025-03-10 | $3.33M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $953.00K 10-Q · filed 2024-11-05 | $2.05M 10-Q · filed 2024-11-05 |